Literature DB >> 29505093

Disease-Drug Interactions in Inflammatory States via Effects on CYP-Mediated Drug Clearance.

David E Coutant1, Stephen D Hall1.   

Abstract

The human inflammatory response can result in the alteration of drug clearance through effects on drug-metabolizing enzymes or drug transporters. In this article, clinical examples are reviewed of how diseases with moderate to severe inflammation can decrease cytochrome P450 (CYP)-mediated drug clearance and alter plasma protein binding. Also examined is how albumin, α-1-acid glycoprotein, drug fraction unbound in plasma, CYP content, and oral clearance can change dynamically with time in response to inflammation.
© 2018, The American College of Clinical Pharmacology.

Entities:  

Keywords:  CYP; albumin; clearance; inflammation; plasma protein binding; rheumatoid arthritis

Mesh:

Substances:

Year:  2018        PMID: 29505093     DOI: 10.1002/jcph.1093

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  9 in total

1.  Pharmacokinetics of Benznidazole in Experimental Chronic Chagas Disease Using the Swiss Mouse-Berenice-78 Trypanosoma cruzi Strain Model.

Authors:  Suzana Marques de Jesus; Leonardo Pinto; Fernanda de Lima Moreira; Glauco Henrique Balthazar Nardotto; Rodrigo Cristofoletti; Luísa Perin; Kátia da Silva Fonseca; Pauliana Barbêdo; Lorena Cera Bandeira; Paula Melo de Abreu Vieira; Claudia Martins Carneiro
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

2.  Regulation of cytochrome P450 enzyme activity and expression by nitric oxide in the context of inflammatory disease.

Authors:  Edward T Morgan; Cene Skubic; Choon-Myung Lee; Kaja Blagotinšek Cokan; Damjana Rozman
Journal:  Drug Metab Rev       Date:  2020-09-08       Impact factor: 4.518

3.  Glutamine-451 Confers Sensitivity to Oxidative Inhibition and Heme-Thiolate Sulfenylation of Cytochrome P450 4B1.

Authors:  Matthew E Albertolle; Hyun D Song; Clayton J Wilkey; Jere P Segrest; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2019-02-11       Impact factor: 3.739

Review 4.  The relationships between cytochromes P450 and H2O2: Production, reaction, and inhibition.

Authors:  Matthew E Albertolle; F Peter Guengerich
Journal:  J Inorg Biochem       Date:  2018-05-23       Impact factor: 4.155

5.  Secukinumab Treatment Does Not Alter the Pharmacokinetics of the Cytochrome P450 3A4 Substrate Midazolam in Patients With Moderate to Severe Psoriasis.

Authors:  Gerard Bruin; Anke Hasselberg; Irina Koroleva; Julie Milojevic; Claudio Calonder; Rachel Soon; Ralph Woessner; David M Pariser; Bruno Boutouyrie-Dumont
Journal:  Clin Pharmacol Ther       Date:  2019-08-03       Impact factor: 6.875

Review 6.  Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview.

Authors:  Haleh Rezaee; Fariba Pourkarim; Samira Pourtaghi-Anvarian; Taher Entezari-Maleki; Touraj Asvadi-Kermani; Masoud Nouri-Vaskeh
Journal:  Pharmacol Res Perspect       Date:  2021-02

Review 7.  The Cytokine Release Syndrome and/or the Proinflammatory Cytokines as Underlying Mechanisms of Downregulation of Drug Metabolism and Drug Transport: A Systematic Review of the Clinical Pharmacokinetics of Victim Drugs of this Drug-Disease Interaction Under Different Clinical Conditions.

Authors:  Milo Gatti; Federico Pea
Journal:  Clin Pharmacokinet       Date:  2022-09-05       Impact factor: 5.577

8.  Comparative Pharmacokinetics of Three Bioactive Diterpenoids of Rabdosia serra Extract in Normal and Con A-Induced Liver Injury Rats Using UPLC-MS/MS.

Authors:  Fangle Liu; Yun Zeng; Pengyu Dai; Kaiwen Huang; Kaihui Zhang; Tao Tao; Meiqi Wang; Chenchen Zhu; Chaozhan Lin
Journal:  Front Pharmacol       Date:  2022-07-12       Impact factor: 5.988

9.  Evaluation of CYP1A2 activity: Relationship between the endogenous urinary 6-hydroxymelatonin to melatonin ratio and paraxanthine to caffeine ratio in dried blood spots.

Authors:  Gaëlle Magliocco; Jules Desmeules; Caroline Flora Samer; Aurélien Thomas; Youssef Daali
Journal:  Clin Transl Sci       Date:  2022-03-26       Impact factor: 4.438

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.